Siduma Therapeutics was developing a novel class of hetero-bifunctional small molecules. Based on work originating in the lab of Craig Crews at Yale, Siduma was designing novel compounds that leverage the innate biology of human cells to target disease causing proteins across a wide range of therapeutic areas.